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The fluoroquinolone class of antimicrobial agents has
had broad acceptance in hospitalized and community
patients, and usage appears to be increasing (1,2). Although
some members of the class (temafloxacin, grepafloxacin, and
trovafloxacin) have been withdrawn or restricted because of
adverse events, new members continue to be developed and
approved (gatifloxacin and moxifloxacin). The last six
released fluoroquinolones are for treating patients with
respiratory tract infections, the single most common group of
infections (3). This fact, plus the convenience of
fluoroquinolones (once or twice a day oral dosing), suggests
that use will increase (1).
As we approach the halfway point of the second decade of
fluoroquinolone use, resistance has already emerged in some
species of bacteria and some clinical settings. We examine the
mechanisms of fluoroquinolone resistance and discuss
epidemiologic factors that may have contributed to the
prevalence of antibiotic resistance in clinical settings.
Mechanism of Fluoroquinolone Action
Fluoroquinolones (and earlier quinolones) are novel
among antimicrobial agents in clinical use because they
directly   inhibit DNA synthesis. Inhibition appears to occur
by interaction of the drug with complexes composed of DNA
and either of the two target enzymes, DNA gyrase and
topoisomerase IV. These enzymes are structurally related to
each other, both being tetrameric with pairs of two different
subunits. The GyrA and GyrB subunits of DNA gyrase are
respectively homologous with the ParC and ParE subunits of
topoisomerase IV. Both enzymes are type 2 topoisomerases,
which act by breaking both strands of a segment of DNA,
passing another segment through the break, and then
resealing the break. For DNA gyrase, this topoisomerization
reaction results in introduction (or removal) of DNA
supercoils, thus affecting the negative supercoiling of DNA
necessary to initiate DNA replication and remove positive
supercoils that accumulate before an advancing replication
fork. For topoisomerase IV, the topoisomerization reaction
results in separation of the interlocking of daughter DNA
strands that develop during replication; this facilitates the
segregation of daughter DNA molecules into daughter cells.
In both cases, fluoroquinolones appear to trap the enzyme on
DNA during the topoisomerization reaction, forming a
physical barrier to the movement of the replication fork (4),
RNA polymerase (5), and DNA helicase (6). The collision of
the replication fork with these trapped complexes triggers
other poorly defined events within the cell that ultimately
result in cell death.
Mechanisms of Fluoroquinolone Resistance
In all species studied, mechanisms of fluoroquinolone
resistance include one or two of the three main mechanistic
categories, alterations in the drug target, and alterations in
the permeation of the drug to reach its target. No specific
quinolone-modifying or -degrading enzymes have been found
as a mechanism of bacterial resistance to fluoroquinolones,
although some fungi can degrade quinolones by metabolic
pathways (7).
Alterations in Target Enzymes
Most extensively studied have been alterations in target
enzymes, which are generally localized to specific domains of
each subunit type. These alterations arise from spontaneous
mutations in the genes encoding the enzyme subunits and
thus can exist in small numbers (1 in 106 to 1 in 109 cells) in
large bacterial populations. With GyrA and ParC subunits of
resistant bacteria, amino acid changes are generally localized
to a region of the enzyme in the amino terminus that contains
the active site, a tyrosine that is covalently linked to the
broken DNA strand during enzyme action. Resistance-
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dimensions, based on the structure of a fragment of GyrA that
has been solved by x-ray crystallography, suggesting that this
region constitutes part of a quinolone-binding site on the
enzyme (8). One of the common resistance mutations in GyrA,
which causes a change from serine at position 83 to
tryptophan, causes reduced binding of norfloxacin to the
gyrase-DNA complex (9).
For the GyrB and ParE subunits of resistant bacteria,
amino acid changes, when present (mutations in these
subunits are much less common than those in GyrA or ParC),
are usually localized to the mid-portion of the subunit in a
domain involved in interactions with their complementary
subunits (GyrA and ParC, respectively). The original crystal
structure of yeast topoisomerase II, which is related to DNA
gyrase and topoisomerase IV, had suggested that this
resistance-determining domain was not in proximity to the
resistance-determining domains of GyrA and ParC (10);
however, structures of other enzyme conformations suggested
that the resistance-determining regions of both types of
subunits might be in proximity during certain parts of the
enzyme catalytic cycle, perhaps defining an enzyme
conformation to which quinolones bind (11). No crystal
structures in which a quinolone is bound to the enzyme-DNA
complex have  been solved; thus, contact points between drug,
enzyme, and DNA have not been directly determined. Also
unknown is how different amino acid changes effect
resistance.
Differences in Fluoroquinolone Targets and Resistance
The interaction of a fluoroquinolone with the complexes
of either DNA gyrase or topoisomerase IV with DNA may
block DNA synthesis and result in cell death (12). The
antibacterial potency of a quinolone is defined in part by its
potency against the two enzyme targets; the more sensitive of
the two enzymes within a cell is the primary target. Many
fluoroquinolones have differing potencies against DNA
gyrase and topoisomerase IV. A general pattern for most
quinolones has emerged: DNA gyrase is the primary drug
target in gram-negative bacteria, and topoisomerase IV is the
primary target in gram-positive bacteria. These differences
correlate with relative drug sensitivities in several cases, the
more sensitive of the two enzymes being the primary target
defined by genetic tests (13-15). The first step in mutational
resistance in the drug target usually occurs by an amino acid
change in the primary enzyme target, with a rise in MIC of the
cell predicted to be determined by the effect of the mutation
itself or by the level of intrinsic sensitivity of the secondary
drug target (whichever is lower). Higher levels of resistance
may then occur by second mutational steps, in which amino
acid changes are selected in the secondary target enzyme.
Further mutations result in additional amino acid changes in
either enzyme, depending on which was least resistant in the
cell under selection. On mechanistic grounds, this pattern of
stepwise mutations in alternating target enzymes implies
that both high intrinsic potency against the primary target
and the similarity of potency against both targets will affect
the likelihood of selection of first-step resistant mutants.
Thus, fluoroquinolones with a high therapeutic index (defined
as the concentration of drug at the site of infection divided by
the MIC of the drug for the target bacterium), in which drug
concentration exceeds the MIC of a first-step mutant, are
unlikely to select spontaneous first-step mutants present in
the infecting bacterial population; such mutants are inhibited
or killed by these concentrations. Furthermore, the greater
the extent to which a fluoroquinolone has similar (and
ultimately equal) potency against both enzyme targets, the
lower the MIC increment for a first-step drug target mutant.
Thus, for drugs with low increments in resistance for first-
step mutants because of similar activities against both target
enzymes, the extent to which drug concentrations can exceed
the MIC of first-step mutants may be enhanced. These
principles would predict that selection of fluoroquinolone
resistance could occur readily with ciprofloxacin against
species such as Staphylococcus aureus and Pseudomonas
aeruginosa, organisms in which single mutations cause MICs
of ciprofloxacin that approach or exceed achievable serum
concentrations. This prediction has been borne out by
surveillance data (16).
Alterations in Drug Permeation
To reach their targets in the cell cytoplasm,
fluoroquinolones must cross the cytoplasmic membrane and,
in gram-negative bacteria, the outer membrane as well.
Fluoroquinolones are sufficiently small and have charge
characteristics that allow them to cross the outer membrane
through porin proteins, which form general diffusion
channels; they also appear to cross the cytoplasmic
membrane by diffusion (17). Resistance to fluoroquinolones in
gram-negative bacteria is associated with reductions in
porins and reduced bacterial accumulation of drug, but
measurements of diffusion rates suggest that porin
reductions alone are generally not sufficient to account for
resistance (18).
More recently, resistance caused by reduced accumula-
tion has been shown to require the presence and enhanced
expression of endogenous efflux systems that actively pump
drug from the cytoplasm. In gram-negative bacteria, these
systems typically have three components: the efflux pump
located in the cytoplasmic membrane, an outer membrane
protein, and a membrane fusion protein thought to link the
two. Drug is actively extruded from the cytoplasm or
cytoplasmic membrane across the periplasm and outer
membrane to the cell exterior; the energy for this process is
derived from the proton gradient across the membranes.
Pumps of this type also exist in gram-positive bacteria, and
increased amounts of these pumps have been associated with
low levels of fluoroquinolone resistance. These efflux systems
are typically capable of causing resistance to compounds of
diverse structural types and thus are referred to as multidrug
resistance (MDR) pumps. They appear to be present in many
if not all bacteria. The natural substrates for these systems
are generally unknown, but current models envision a general
role in removing toxic compounds from the cytoplasm or
cytoplasmic membrane (19). Although fluoroquinolones are
synthetic antimicrobial agents, a number of them are
substrates for a range of efflux systems. Among pathogenic
bacteria,  Escherichia coli,  P. aeruginosa,  S. aureus, and
Streptococcus pneumoniae have been most extensively
studied for efflux systems causing fluoroquinolone resistance
(Table). In most cases, expression of the components of the
efflux system is regulated, and resistance occurs by
chromosomal mutation that causes coordinated increased
expression of pump components. The conditions under which
there is physiologically increased expression of these systems
are largely unknown. In P. aeruginosa, four such efflux
systems have been identified, each differing by which339 Vol. 7, No. 2, March–April 2001 Emerging Infectious Diseases
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fluoroquinolones are preferred substrates (20). It appears
likely that most bacteria will have multiple MDR efflux
systems.
The structural features of a fluoroquinolone that
determine whether it is affected by an efflux system are not
fully defined but correlate with hydrophilicity in the NorA
pump of S. aureus (21). The risk for acquisition of resistance
may be reduced for quinolones that are poor substrates for
efflux pumps, since overexpression of such pumps would be
unlikely to be effective as a resistance mechanism. Inhibition
of pump function by other compounds is also under
investigation as a means of reducing the frequency of
resistance selections (22) and enhancing intrinsic activity of
fluoroquinolones and other drugs that are also pump
substrates.
Other Mechanisms of Resistance
The dominant mechanisms of fluoroquinolone resistance
identified are 1) chromosomal mutations causing reduced
affinity of DNA gyrase and topoisomerase IV for
fluoroquinolones and 2) overexpression of endogenous MDR
pumps. One report, however, has documented plasmid-
mediated fluoroquinolone resistance in clinical isolates of
Klebsiella pneumoniae, transferable to E. coli in the
laboratory (23). Neither the mechanism of this transferable
resistance nor the prevalence of fluoroquinolone-resistance
plasmids in clinical settings is known.
Clinical Occurrence of Fluoroquinolone Resistance
Fluoroquinolone resistance emerged shortly after these
drugs were introduced; two species were particularly affected,
S. aureus and P. aeruginosa. Ciprofloxacin and ofloxacin were
the most extensively used fluoroquinolones during this early
period. The emergence of resistance was predicted on
molecular grounds because, in these species, single
mutations, which raise the MIC of ciprofloxacin of these
organisms 4- to 16-fold, produce a level of resistance at or
above peak drug concentrations achievable in serum,
providing an opportunity for spontaneous first-step mutants
to survive and emerge when a patient is exposed to
fluoroquinolones. In the case of S. aureus and coagulase-
negative staphylococci, methicillin-resistant strains devel-
oped fluoroquinolone resistance more rapidly than methicil-
lin-susceptible strains (1,24). This difference is in part
explained by nosocomial transmission in some settings and by
the potential for coselection with several antimicrobial agents
(because of the common multidrug resistance phenotype of
methicillin-resistant strains [25]). Case-control studies have
identified fluoroquinolone use as a risk factor for resistance.
Fluoroquinolone resistance has also increased substan-
tially in some settings in species in which multiple
mutational events are required for resistance to occur (e.g.,
Campylobacter jejuni [26], E. coli [27], and Neisseria
gonorrhoeae [28]). Emergence in these species would not have
been predicted on molecular grounds, suggesting that other
epidemiologic factors may have come into play. For C. jejuni,
resistance emerged in parallel in animal and human
populations (29) shortly after fluoroquinolones were
introduced for use in humans and other quinolones were
introduced in food animal production, particularly poultry, in
parts of Europe. In the United States, where use of quinolones
in food animals was introduced later, demonstrating a link
between resistant C. jejuni strains from poultry and food
products and those causing human disease was possible (26).
Thus, for a known zoonotic pathogen such as C. jejuni,
resistance was augmented by selection pressures in an
animal reservoir of campylobacters.
Fluoroquinolone resistance in E. coli has emerged in
Europe, particularly in patients with urinary tract infections
(30) and neutropenic cancer patients with bacteremia that
developed during fluoroquinolone prophylaxis (31). Fecal
carriage of resistant E. coli, however, appears to be common in
both healthy adults and children in Spain (27). Carriage of
resistant strains by children, a group in which fluoroquinolones
are rarely used, and by adults without prior quinolone
exposures (30) suggests acquisition of resistant strains by the
population at large. This occurrence (in the context of
documented high rates of fluoroquinolone resistance in E. coli
isolated from poultry in Spain [32] and, by analogy, to what
has been documented with campylobacters) suggests that
acquisition of resistant strains from food sources may have
resulted in substantial colonization of the human population
with resistant E. coli, creating a reservoir of resistant
organisms. Fluoroquinolone use in humans, which has also
been shown to be a risk factor for having a resistant strain,
may operate in this context to select either already fully
resistant or intermediately resistant strains, accounting for
the high levels of resistance and multiple mutations reported
in resistant strains causing infections in humans. Whether
similar problems with fluoroquinolone-resistant E. coli will
emerge in the United States is not known, but the situation is
being monitored.
Humans are the sole reservoir for infections with
N. gonorrhoeae. In the United States, fluoroquinolone
resistance in this organism has resulted largely from clonal
outbreaks caused by human-to-human spread (33). Thus, for
all three organisms in which fluoroquinolone resistance has
become problematic despite a requirement for multiple
mutations, other epidemiologic factors (of transmission and
ongoing selection in reservoir populations of organisms)
appear to be at work.
Newer fluoroquinolones are now incorporated into
guidelines for treatment of patients with lower respiratory
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tract infections because of rising resistance to beta-lactams
and other agents in S. pneumoniae, the most commonly
identified bacterial pathogen in patients with community-
acquired pneumonia (34). Only recently has fluoroquinolone
resistance begun to emerge in this organism, albeit at low
levels (2). In some cases, fluoroquinolone-resistant strains,
like those resistant to beta-lactams, have emerged because of
clonal spread (35). Because the newest fluoroquinolones are
for treating patients with respiratory tract infections,
increasing selection pressure for resistance is possible. This
concern is especially great for drugs developed  for use in
children, who are a major reservoir of S. pneumoniae (36).
Monitoring will be necessary, as will studies to indicate
whether the improved therapeutic index for some
fluoroquinolones can be translated into a lower risk of
selection of resistant strains, either spontaneous or clonal, in
the clinical setting.
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